百奥泰：公司在研药品维拉西塔单抗注射液（BAT5906）上市许可申请获受理

Core Viewpoint - The company Baiotai has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of its investigational drug, Vela-sitran monoclonal antibody injection [1] Group 1: Product Information - Vela-sitran is classified as a Class 1 biological product for the treatment of neovascular (wet) age-related macular degeneration (nAMD) [1] - BAT5906 is an innovative drug developed and produced by Baiotai, characterized as a recombinant humanized monoclonal antibody [1] - The drug is an IgG1 type full-length antibody with a molecular weight of 149 kDa, specifically binding to human VEGF-A165 to inhibit neovascularization [1]